READ: Stars and Bid Forum: Prime's Medicare clients lead the way - Prime Therapeutics
READ: Stars and Bid Forum: Prime's Medicare clients lead the way
Prime Therapeutics (Prime) and its Medicare clients are outperforming the industry in Medicare Star Ratings, with 43% of our Medicare Advantage Prescription Drug (MAPD) contracts achieving 4+ stars.
This distinction not only drives millions of dollars in quality bonus payments but also helps attract more members by allowing clients to reinvest these dollars to lower premiums, offer additional benefits, or lower cost sharing.
To build on this success and to plan for the future, nearly 100 representatives from Prime’s 16 Medicare clients gathered last month at the annual Stars and Bid Forum, the first of many client meetings to prepare for the 2026 Medicare bid deadline in June 2025 and Star ratings strategies.
The main stage for the two-day event featured thought leaders exploring the forces reshaping the Medicare landscape and Prime executives discussing strategic priorities, including Inflation Reduction Act (IRA) implications, technology transformation, the JUDI® migration and a Medicare Prescription Payment Program (M3P) client panel discussion. Prime’s subject matter experts (SMEs) led breakout sessions focusing on Star Ratings opportunities and planning for the rapidly approaching 2026 bid.
“Medicare is very complex and constantly changing,” said Jason Moore, vice president of government programs, client strategy. “As the Medicare and Star ratings landscape evolves, we’re investing in our Center of Excellence teams to help clients navigate these changes and deliver exceptional value to their members.”